China Universal Asset Management Co., Ltd. Nkarta, Inc. Transaction History

China Universal Asset Management Co., Ltd.

$893 Million
Q3 2024

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 May 21, 2024	BUY	$1.39 - $2.29 $867 - $1,428	624 Added 97.35%	1,265 $1,000
Q3 2023 Oct 30, 2023	BUY	$1.39 - $2.29 $867 - $1,428	624 Added 97.35%	1,265 $2,000
Q2 2023 May 21, 2024	SELL	$2.19 - $5.17 $43 - $103	-20 Reduced 3.03%	641 $1,000
Q2 2023 Jul 27, 2023	SELL	$2.19 - $5.17 $43 - $103	-20 Reduced 3.03%	641 $1,000
Q1 2023 May 21, 2024	BUY	$3.37 - $6.3 $556 - $1,039	165 Added 33.27%	661 $2,000
Q1 2023 Apr 27, 2023	BUY	$3.37 - $6.3 $556 - $1,039	165 Added 33.27%	661 $2,000
Q4 2022 May 21, 2024	BUY	$5.14 - $14.35 $2,549 - $7,117	496 New	496 $2,000
Q4 2022 Jan 31, 2023	BUY	$5.14 - $14.35 $205 - $574	40 Added 8.77%	496 $3,000
Q3 2022 Oct 21, 2022	BUY	$12.27 - $18.39 $5,595 - $8,385	456 New	456 $6,000

Others Institutions Holding NKTX

# of Institutions

129

Shares Held

66.5M

Call Options Held

173K

Put Options Held

20K

Ra Capital Management, L.P. Boston, MA

10.8M
Shares

$28.2 Million
0.68% of portfolio
Commodore Capital LP New York, NY

4.66M
Shares

$12.2 Million
1.79% of portfolio
Black Rock Inc. New York, NY

4.06M
Shares

$10.6 Million
0.0% of portfolio
Boxer Capital, LLC San Diego, CA

4.03M
Shares

$10.5 Million
0.97% of portfolio
Samsara Bio Capital, LLC Palo Alto, CA

3.77M
Shares

$9.83 Million
9.87% of portfolio

View Full List

About Nkarta, Inc.

Ticker NKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,656,800
Market Cap $127M
Description
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the sur...

More about NKTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.

Account